PT  - JOURNAL ARTICLE
AU  - Bettiol, Alessandra
AU  - Sinico, Renato Alberto
AU  - Schiavon, Franco
AU  - Monti, Sara
AU  - Bozzolo, Enrica Paola
AU  - Franceschini, Franco
AU  - Govoni, Marcello
AU  - Lunardi, Claudio
AU  - Guida, Giuseppe
AU  - Lopalco, Giuseppe
AU  - Paolazzi, Giuseppe
AU  - Vacca, Angelo
AU  - Gregorini, Gina
AU  - Leccese, Pietro
AU  - Piga, Matteo
AU  - Conti, Fabrizio
AU  - Fraticelli, Paolo
AU  - Quartuccio, Luca
AU  - Alberici, Federico
AU  - Salvarani, Carlo
AU  - Bettio, Silvano
AU  - Negrini, Simone
AU  - Selmi, Carlo
AU  - Sciascia, Savino
AU  - Moroni, Gabriella
AU  - Colla, Loredana
AU  - Manno, Carlo
AU  - Urban, Maria Letizia
AU  - Vannacci, Alfredo
AU  - Pozzi, Maria Rosa
AU  - Fabbrini, Paolo
AU  - Polti, Stefano
AU  - Felicetti, Mara
AU  - Marchi, Maria Rita
AU  - Padoan, Roberto
AU  - Delvino, Paolo
AU  - Caporali, Roberto
AU  - Montecucco, Carlomaurizio
AU  - Dagna, Lorenzo
AU  - Cariddi, Adriana
AU  - Toniati, Paola
AU  - Tamanini, Silvia
AU  - Furini, Federica
AU  - Bortoluzzi, Alessandra
AU  - Tinazzi, Elisa
AU  - Delfino, Lorenzo
AU  - Badiu, Iuliana
AU  - Rolla, Giovanni
AU  - Venerito, Vincenzo
AU  - Iannone, Florenzo
AU  - Berti, Alvise
AU  - Bortolotti, Roberto
AU  - Racanelli, Vito
AU  - Jeannin, Guido
AU  - Padula, Angela
AU  - Cauli, Alberto
AU  - Priori, Roberta
AU  - Gabrielli, Armando
AU  - Bond, Milena
AU  - Tedesco, Martina
AU  - Pazzola, Giulia
AU  - Tomietto, Paola
AU  - Pellecchio, Marco
AU  - Marvisi, Chiara
AU  - Maritati, Federica
AU  - Palmisano, Alessandra
AU  - Dejaco, Christian
AU  - Willeit, Johann
AU  - Kiechl, Stefan
AU  - Olivotto, Iacopo
AU  - Willeit, Peter
AU  - Prisco, Domenico
AU  - Vaglio, Augusto
AU  - Emmi, Giacomo
AU  - , 
TI  - Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome)
AID  - 10.1101/2020.11.09.20228197
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.09.20228197
4099  - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228197.short
4100  - http://medrxiv.org/content/early/2020/11/12/2020.11.09.20228197.full
AB  - Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA).This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.Methods We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.Results 129 EGPA patients (22.5%) had AVTE, considered as potentially life-threatening in 55.8%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score ≥20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.Conclusion EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective observational studyFunding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the Declaration of Helsinki and approved by the Ethic Committee of the University Hospital Careggi, Florence, Italy (Approval number 12804/CAM_BIO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data are available upon reasonable request, to be sent by email to the corresponding author.